19 June 2013
Keywords: ardea, rdea119, reduces, damage, uc, model, usa-based
Article | 13 October 2008
USA-based Ardea Biosciences says data from a preclinical study of RDEA119, its lead mitogen-activated ERK kinase inhibitor, showed it to
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 October 2008
18 June 2013
© 2013 thepharmaletter.com